Erste Group Bank Has Positive Outlook of NVO FY2026 Earnings

Key Points

• Erste Group Bank raised Novo Nordisk’s FY2026 EPS estimate to $3.27 from $3.20, though the forecast remains below the $3.39 analyst consensus.
• Novo Nordisk reported quarterly revenue of $11.98 billion and EPS of $0.94, with a 35.36% net margin and 61.20% return on equity.
• Analyst sentiment remains cautious: the stock has a consensus “Hold” rating from MarketBeat, despite an average price target around $65.81 versus its recent price near $47.59.

Novo Nordisk A/S (NYSE:NVO - Free Report) - Equities research analysts at Erste Group Bank increased their FY2026 earnings per share (EPS) estimates for shares of Novo Nordisk A/S in a research note issued to investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.27 per share for the year, up from their prior estimate of $3.20. The consensus estimate for Novo Nordisk A/S's current full-year earnings is $3.39 per share.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion during the quarter.

NVO has been the subject of a number of other reports. Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Zacks Research cut Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Monday, July 13th. HSBC reaffirmed a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Citigroup reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Nordea Equity Research upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Friday, June 19th. Five research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus target price of $65.81.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $47.59 on Tuesday. The company has a 50-day simple moving average of $47.07 and a 200 day simple moving average of $44.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company has a market capitalization of $212.49 billion, a PE ratio of 11.64, a price-to-earnings-growth ratio of 4.31 and a beta of 0.76.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be issued a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S's dividend payout ratio is 42.79%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently bought and sold shares of the stock. Loomis Sayles & Co. L P lifted its stake in shares of Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company's stock valued at $871,848,000 after purchasing an additional 969,916 shares during the period. Franklin Resources Inc. raised its position in shares of Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company's stock worth $748,064,000 after purchasing an additional 717,719 shares during the last quarter. Morgan Stanley increased its stake in Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company's stock valued at $653,406,000 after purchasing an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company's stock valued at $492,940,000 after acquiring an additional 4,836,285 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Novo Nordisk A/S during the 1st quarter valued at $287,660,000. 11.54% of the stock is owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Analysts set an average price target of $65.56 for Novo Nordisk, substantially above the stock’s recent trading level near $47.59. If achieved, the target would imply roughly 38% upside and may support buying interest. Analysts Set Novo Nordisk A/S Price Target at $65.56
• Positive Sentiment: Erste Group Bank raised its fiscal 2026 earnings-per-share forecast for Novo Nordisk to $3.27 from $3.20. The revised estimate remains below the $3.39 consensus, but the upward revision signals improving analyst expectations for profitability. Erste Group Bank Raises Novo Nordisk Earnings Estimate
• Positive Sentiment: Novo Nordisk named Amazon Web Services its preferred global cloud and strategic artificial-intelligence partner. A new London innovation hub and AWS tools are intended to accelerate drug discovery, therapy design and clinical-data analysis; more than 25,000 Novo employees have already used the technology. The partnership could improve research efficiency and strengthen the company’s long-term pipeline. Novo Nordisk, Amazon Web Services Collaborate to Advance Drug Discovery for Chronic Diseases
• Positive Sentiment: Veru reported that its semaglutide combination trial is fully enrolled and remains on track for interim results in the first quarter of 2027. Novo Nordisk is supplying clinical product, potentially expanding the use of its semaglutide platform, though the financial impact is not yet clear. Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Trial Progress
• Neutral Sentiment: Investors continue to compare Novo Nordisk with Eli Lilly as manufacturing capacity becomes a potential competitive advantage in the obesity-drug market. The article highlights both the scale of the opportunity and the intensity of competition. Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source